Guest guest Posted June 22, 2003 Report Posted June 22, 2003 - <vizual Sunday, June 22, 2003 4:45 PM AstraZeneca Pleads Guilty in Cancer Medicine Scheme--- NYTArticle Illustrates Why IAHF Fights On > > New York Times, 21 June 2003 > > > Source: > http://www.nytimes.com/2003/06/21/business/21CANC.html?ex=1056772800 & amp;en= > ac2944953bc14917 & amp;ei=5062 & amp;partner=GOOGLE > > > AstraZeneca Pleads Guilty in Cancer Medicine Scheme > > By MELODY PETERSEN > > > WILMINGTON, Del., June 20 - AstraZeneca, the large pharmaceutical company, > pleaded guilty today to a felony charge of health care fraud and agreed to > pay $355 million to settle criminal and civil accusations that it engaged in > a nationwide scheme to illegally market a prostate cancer drug. > > The government said the company's employees had given illegal financial > inducements to as many as 400 doctors across the country to persuade them to > prescribe the drug, Zoladex. Those inducements included thousands of free > samples of Zoladex, worth hundreds of dollars each, which the physicians > then billed to Medicare and other federal health care programs, prosecutors > said. The company also gave doctors financial grants, paid them as > consultants and provided free travel and entertainment, the government said. > > The $355 million that AstraZeneca, a British company, agreed to pay is among > the largest settlements in a heath care fraud case. Of that amount, about > $64 million is a criminal fine. The company will pay about $266 million to > the federal government to settle most of the civil accusations. An > additional $25 million will go to settle accusations that it defrauded the > Medicaid programs, which are partly financed by the states. > > The largest fine for health care fraud came in a settlement in October 2001 > by TAP Pharmaceutical Products. It agreed to pay $875 million to settle > criminal and civil accusations that it had engaged in a scheme that largely > mirrors the allegations made by prosecutors against AstraZeneca. > > " We want doctors to prescribe what is best for their patients and not what > is best for the doctor's bank account, " Richard G. Andrews, first assistant > United States attorney for the District of Delaware, said at a news > conference. He and other prosecutors said the government's action should > send a message to all pharmaceutical companies that such conduct will not be > tolerated. > > Prosecutors said that they did not plan to charge any AstraZeneca employees > for the illegal activities that they say began in 1991 and continued until > last year. > > " The investigation did not discover any evidence to implicate AstraZeneca's > upper levels of management, " Mr. Andrews said. > > Mr. Andrews said that AstraZeneca had reported false and inflated prices for > Zoladex to the federal government so that doctors could earn significant > profits by prescribing the drug. Medicare reimbursed the doctors based on > the inflated prices that AstraZeneca reported, he said, while the company > charged doctors for the drug at deep discounts. > > For example, the company reported to the government that the average > wholesale price for a monthly dose of Zoladex was about $300, prosecutors > said, but doctors were charged about $170 for that dose. That resulted in a > $130 profit to the doctor, the government said. > > Rachel Bloom-Baglin, a spokeswoman for AstraZeneca, said today that the > company was accepting responsibility for giving doctors free samples of > Zoladex with the understanding that they would bill the government for them. > These activities, which took place from 1993 to 1996, resulted in the > criminal charge. > > But she said that the company disagreed with prosecutors on the other > charges, including the accusation that it had provided false and inflated > pricing information to the government. > > " We disagree with the government on this, but to put it behind us, we are > agreeing to a settlement today, " Ms. Bloom-Baglin said. " We believe that > this is in the best interest of our company and employees. " > > " We strongly believe that the pricing for Zoladex was at all times lawful, " > she added. > > Zoladex is one of a limited number of medicines that doctors buy directly > from drug companies and that Medicare now pays for. Many of these medicines > are used for cancer patients and are administered in doctors' offices. > > Earlier, the government charged three urologists with conspiring to bill the > free Zoladex samples they received from the company to the federal > government. Two of those doctors have pleaded guilty and await sentencing. > > " Whether any further doctors should be charged is an ongoing question, " Mr. > Andrews said. > > The government's seven-year investigation of the marketing of Zoladex began > after an executive at TAP, a competitor, filed a whistle-blower lawsuit > against both TAP and AstraZeneca, prosecutors said. > > The two companies compete aggressively in the prostate cancer market, with > TAP, a joint venture of Abbott Laboratories and Takeda Chemical Industries, > selling a drug called Lupron. Both drugs are considered equally effective at > halting the production of testosterone, but they are administered > differently. Zoladex consists of tiny pellets that must be injected with a > larger needle than that used for Lupron, which comes in a liquid form. > > The criminal investigation in the TAP case is continuing. More than a dozen > current and former employees have been charged with conspiracy to pay > kickbacks to doctors, including Alan MacKenzie, who was the president of > Takeda Pharmaceuticals North America at the time of the indictments. One > employee has pleaded guilty; the others have denied any wrongdoing. > > Several urologists were also charged in the TAP case. > > The whistle-blower, Douglas N. Durand, a former vice president for sales at > TAP, will receive $47.5 million of the settlement in the AstraZeneca case as > allowed by federal law. Mr. Durand already received $77 million from the TAP > case. > > Lupron has long dominated the market and prosecutors said that was why > AstraZeneca was not forced to pay as high a fine as TAP. Sales of Lupron > were $876 million in the United States last year, compared with $212 million > for Zoladex. > > The two cases are part of a growing number of investigations and lawsuits > into the marketing practices of pharmaceutical companies. AstraZeneca > disclosed earlier this year that federal prosecutors in Boston had requested > documents about the sale of Prilosec, a drug for ulcers and severe > heartburn. The company also said the Federal Trade Commission was > investigating its advertising and marketing of Nexium, the company's new > heartburn drug. > ------------PLEASE FORWARD THIS WIDELY!!!! > > PLEASE DONATE TO ANH LAWSUIT TO OVERTURN THE EU FOOD SUPPLEMENT DIRECTIVE!!! > HUGE GLOBAL IMPLICATIONS!!! > DONATE VIA http://www.alliance-natural-health.org want info? > http://www.iahf.com/anh_lawsuit.html also > http://www.lef.org/magazine/mag2003/2003_preprint_eu_01.html > > Donate to IAHF via http://www.iahf.com (paypal) or IAHF POB 10632 Blacksburg > VA 24062 USA and lets keep this ball rolling, we WILL WIN! > International Advocates for Health Freedom > POB 10632 Blacksburg VA 24062 USA > http://www.iahf.com; http://iadsa-exposed.tripod.com > 800-333-2553 N.America > 540-961-0476 World > > Quote
Guest guest Posted June 23, 2003 Report Posted June 23, 2003 - <vizual Sunday, June 22, 2003 4:45 PM AstraZeneca Pleads Guilty in Cancer Medicine Scheme--- NYTArticle Illustrates Why IAHF Fights On > > New York Times, 21 June 2003 > > > Source: > http://www.nytimes.com/2003/06/21/business/21CANC.html?ex=1056772800 & amp;en= > ac2944953bc14917 & amp;ei=5062 & amp;partner=GOOGLE > > > AstraZeneca Pleads Guilty in Cancer Medicine Scheme > > By MELODY PETERSEN > > > WILMINGTON, Del., June 20 - AstraZeneca, the large pharmaceutical company, > pleaded guilty today to a felony charge of health care fraud and agreed to > pay $355 million to settle criminal and civil accusations that it engaged in > a nationwide scheme to illegally market a prostate cancer drug. > > The government said the company's employees had given illegal financial > inducements to as many as 400 doctors across the country to persuade them to > prescribe the drug, Zoladex. Those inducements included thousands of free > samples of Zoladex, worth hundreds of dollars each, which the physicians > then billed to Medicare and other federal health care programs, prosecutors > said. The company also gave doctors financial grants, paid them as > consultants and provided free travel and entertainment, the government said. > > The $355 million that AstraZeneca, a British company, agreed to pay is among > the largest settlements in a heath care fraud case. Of that amount, about > $64 million is a criminal fine. The company will pay about $266 million to > the federal government to settle most of the civil accusations. An > additional $25 million will go to settle accusations that it defrauded the > Medicaid programs, which are partly financed by the states. > > The largest fine for health care fraud came in a settlement in October 2001 > by TAP Pharmaceutical Products. It agreed to pay $875 million to settle > criminal and civil accusations that it had engaged in a scheme that largely > mirrors the allegations made by prosecutors against AstraZeneca. > > " We want doctors to prescribe what is best for their patients and not what > is best for the doctor's bank account, " Richard G. Andrews, first assistant > United States attorney for the District of Delaware, said at a news > conference. He and other prosecutors said the government's action should > send a message to all pharmaceutical companies that such conduct will not be > tolerated. > > Prosecutors said that they did not plan to charge any AstraZeneca employees > for the illegal activities that they say began in 1991 and continued until > last year. > > " The investigation did not discover any evidence to implicate AstraZeneca's > upper levels of management, " Mr. Andrews said. > > Mr. Andrews said that AstraZeneca had reported false and inflated prices for > Zoladex to the federal government so that doctors could earn significant > profits by prescribing the drug. Medicare reimbursed the doctors based on > the inflated prices that AstraZeneca reported, he said, while the company > charged doctors for the drug at deep discounts. > > For example, the company reported to the government that the average > wholesale price for a monthly dose of Zoladex was about $300, prosecutors > said, but doctors were charged about $170 for that dose. That resulted in a > $130 profit to the doctor, the government said. > > Rachel Bloom-Baglin, a spokeswoman for AstraZeneca, said today that the > company was accepting responsibility for giving doctors free samples of > Zoladex with the understanding that they would bill the government for them. > These activities, which took place from 1993 to 1996, resulted in the > criminal charge. > > But she said that the company disagreed with prosecutors on the other > charges, including the accusation that it had provided false and inflated > pricing information to the government. > > " We disagree with the government on this, but to put it behind us, we are > agreeing to a settlement today, " Ms. Bloom-Baglin said. " We believe that > this is in the best interest of our company and employees. " > > " We strongly believe that the pricing for Zoladex was at all times lawful, " > she added. > > Zoladex is one of a limited number of medicines that doctors buy directly > from drug companies and that Medicare now pays for. Many of these medicines > are used for cancer patients and are administered in doctors' offices. > > Earlier, the government charged three urologists with conspiring to bill the > free Zoladex samples they received from the company to the federal > government. Two of those doctors have pleaded guilty and await sentencing. > > " Whether any further doctors should be charged is an ongoing question, " Mr. > Andrews said. > > The government's seven-year investigation of the marketing of Zoladex began > after an executive at TAP, a competitor, filed a whistle-blower lawsuit > against both TAP and AstraZeneca, prosecutors said. > > The two companies compete aggressively in the prostate cancer market, with > TAP, a joint venture of Abbott Laboratories and Takeda Chemical Industries, > selling a drug called Lupron. Both drugs are considered equally effective at > halting the production of testosterone, but they are administered > differently. Zoladex consists of tiny pellets that must be injected with a > larger needle than that used for Lupron, which comes in a liquid form. > > The criminal investigation in the TAP case is continuing. More than a dozen > current and former employees have been charged with conspiracy to pay > kickbacks to doctors, including Alan MacKenzie, who was the president of > Takeda Pharmaceuticals North America at the time of the indictments. One > employee has pleaded guilty; the others have denied any wrongdoing. > > Several urologists were also charged in the TAP case. > > The whistle-blower, Douglas N. Durand, a former vice president for sales at > TAP, will receive $47.5 million of the settlement in the AstraZeneca case as > allowed by federal law. Mr. Durand already received $77 million from the TAP > case. > > Lupron has long dominated the market and prosecutors said that was why > AstraZeneca was not forced to pay as high a fine as TAP. Sales of Lupron > were $876 million in the United States last year, compared with $212 million > for Zoladex. > > The two cases are part of a growing number of investigations and lawsuits > into the marketing practices of pharmaceutical companies. AstraZeneca > disclosed earlier this year that federal prosecutors in Boston had requested > documents about the sale of Prilosec, a drug for ulcers and severe > heartburn. The company also said the Federal Trade Commission was > investigating its advertising and marketing of Nexium, the company's new > heartburn drug. > ------------PLEASE FORWARD THIS WIDELY!!!! > > PLEASE DONATE TO ANH LAWSUIT TO OVERTURN THE EU FOOD SUPPLEMENT DIRECTIVE!!! > HUGE GLOBAL IMPLICATIONS!!! > DONATE VIA http://www.alliance-natural-health.org want info? > http://www.iahf.com/anh_lawsuit.html also > http://www.lef.org/magazine/mag2003/2003_preprint_eu_01.html > > Donate to IAHF via http://www.iahf.com (paypal) or IAHF POB 10632 Blacksburg > VA 24062 USA and lets keep this ball rolling, we WILL WIN! > International Advocates for Health Freedom > POB 10632 Blacksburg VA 24062 USA > http://www.iahf.com; http://iadsa-exposed.tripod.com > 800-333-2553 N.America > 540-961-0476 World > > Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.